Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition
November 03, 2022 09:52 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data from its...
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022
October 27, 2022 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference...
Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer
October 25, 2022 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the initiation...
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China
September 26, 2022 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND...
Corvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it will...
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
August 08, 2022 16:05 ET
|
Corvus Pharmaceuticals, Inc.
Prioritizing Development of CPI-818 for T Cell Lymphomas, Autoimmune and Allergic Diseases Plans to Begin Phase 2 Clinical Trial of Ciforadenant in Front Line Renal Cell Cancer (RCC) in Partnership...
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 8, 2022
July 28, 2022 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference...
Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research
July 21, 2022 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the appointment...
Corvus Pharmaceuticals Provides Program Updates at R&D Symposium
May 10, 2022 07:30 ET
|
Corvus Pharmaceuticals, Inc.
Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas Program covers scientific rationale, preclinical and clinical data for its three programs –...
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
May 05, 2022 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today provided a business update...